Abbott Laboratories Analyst Is Bullish About MedTech, Non-MedTech Growth
Abbott Laboratories Analyst Is Bullish About MedTech, Non-MedTech Growth
Abbott Laboratories's (NYSE:ABT) MedTech portfolio is growing at a CAGR (compounded annual growing rate) of 11%-13%.
雅培實驗室（NYSE:ABT）的醫療科技投資組合以每年11%-13%的複合年增長率增長。
The company's non-MedTech operations are expanding by low-to-mid single-digit percentages, according to Oppenheimer.
根據Oppenheimer的說法，該公司的非醫療科技業務正以低至中個位數的百分比擴張。
Analyst Suraj Kalia initiated coverage of Abbott Laboratories with an Outperform rating and price target of $130.
分析師Suraj Kalia開始覆蓋雅培實驗室，並給出了$130的表現評級和價格目標。
The Abbott Laboratories Thesis: The company's MedTech portfolio currently contributes around 45% of total sales of about $42 billion, Kalia said in the initiation note.
雅培實驗室的論點：卡利亞在啓動筆記中稱，公司的醫療科技投資組合目前約佔總銷售額約420億美元的45%。
Check out other analyst stock ratings.
查看其他分析師的股票評級。
Abbott's product pipeline boosts confidence in the company's long-term growth, the analyst stated.
雅培的產品管道增強了對公司長期增長的信懇智能，該分析師稱。
While its various offerings provide "structural advantages for product bundling," the company has also made disciplined MedTech acquisitions, he added.
儘管其各種產品提供了"產品捆綁的結構優勢"，但該公司還進行了紀律嚴明的醫療科技收購，他補充道。
On the non-MedTech side, Nutrition and Diagnostics sales comps will ease over the next few years, driving revenue growth with margin expansion of 30 to 50 basis points per year in fiscal 2026 and beyond, Kalia further wrote.
在非醫療科技方面，營養和診斷銷售的對比將在未來幾年內放緩，在2026財年及以後，Kalia進一步寫道，將帶動收入增長和每年30至50個點子的利潤率擴張。
Price Action: Shares of Abbott Laboratories had risen by 0.7% to $114.17 at the time of publication on Tuesday.
股價走勢：在週二發佈時，雅培股票上漲了0.7%，至114.17美元。
Read More:
閱讀更多：
- Expanding Continuous Glucose Monitoring Options: How Glucotrack Is Helping Usher In The Next Generation Of Diabetes Care Technology
- 拓展連續血糖監測期權：Glucotrack如何幫助迎接糖尿病護理科技的下一代
Image: Shutterstock
圖片：shutterstock
譯文內容由第三人軟體翻譯。
